Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript May 1, 2025Blueprint Medicines Corporation misses on earnings expectations.
Blueprint Medicines Corp (BPMC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | BIT Capital GmbH Jan Beckers | 77,802 | $6,886,255 | -2% | 0.59% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 45,200 | $4,000,652 | -5% | 0.04% |
| 3. | Royce & Associates Chuck Royce | 18,001 | $1,593,269 | 0.02% | |
| 4. | Neo Ivy Capital Renee Yao | 5,754 | $509,286 | 0.16% | |
| 5. | Bayforest Capital Theodoros Tsagaris | 13 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $43.98 | 1,100 | 92,281 | 2022-11-03 | Filing | ||
| $82.66 | 10 | 5,822 | 2021-07-13 | Filing | ||
| $59.98 | 5,000 | 10,812 | 2022-03-03 | Filing | ||
| $18.00 | 125,000 | Large Shareholder, Other | 2,500,711 | 2015-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $103.56 | 144 | 66,992 | 2025-05-05 | Filing | ||
| $102.82 | 180 | 67,136 | 2025-05-05 | Filing | ||
| $101.77 | 1,343 | 67,316 | 2025-05-05 | Filing | ||
| $100.97 | 607 | 68,659 | 2025-05-05 | Filing | ||
| $104.78 | 100 | 16,944 | 2025-05-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,710,708 | $593,964,767 | 0.01% | |
| 2. | 6,640,523 | $587,752,692 | 0.01% | |
| 3. | 1,429,668 | $126,539,915 | 0.36% | |
| 4. | 954,596 | $84,525,504 | 0.09% | |
| 5. | 926,668 | $82,019,384 | 0.01% |
News See All
20 Takeover Rumors Hedge Funds Are Buying
Hedge funds tend to pile up on a stock that gains or is expected to gain positive attention in a market.
10 Best Mid Cap Biotech Stocks to Buy
On March 6, Jared Holz, Mizuho health care equity strategist, appeared on CNBC's 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
12 Most Promising Biotech Stocks According to Wall Street Analysts
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
10 Oversold Biotech Stocks to Buy Now
Biotechnology stocks are among the most volatile in the market, primarily due to the high risks associated with their performance.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q4 2024 Earnings Call Transcript February 13, 2025Blueprint Medicines Corporation misses on earnings expectations.
Why These 15 Stocks Are Skyrocketing in 2025
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript
Operator: Good morning. My name is Nadia, and I'll be your conference operator today.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Call Transcript
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2024 Earnings Call Transcript August 1, 2024Blueprint Medicines Corporation beats earnings expectations.
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2024 Earnings Call Transcript
Blueprint Medicines Corporation misses on earnings expectations. Reported EPS is $ EPS, expectations were $-1.64.
Billionaire Hedge Funds
